Literature DB >> 21504259

Quality of anticoagulation control among patients with atrial fibrillation.

Osnat C Melamed1, Gilad Horowitz, Asher Elhayany, Shlomo Vinker.   

Abstract

OBJECTIVE: To assess the level of anticoagulation control achieved in patients with atrial fibrillation (AF) receiving routine medical care within a large managed care organization and to explore patient factors that influence control. STUDY
DESIGN: Retrospective cross-sectional study of all patients with AF treated in Clalit Health Services (CHS) community clinics in central Israel between November 1, 2006, to October 31, 2007.
METHODS: Using the CHS computerized database, we identified 906 patients with a diagnosis of AF who were treated with warfarin for at least 6 months. Data included patient demographics, comorbidities, and international normalized ratio (INR) values as well as managing physician certification. Anticoagulation control was assessed by measurement of time within therapeutic range (TTR) (INR 2-3). Univariate and multivariate analyses were performed to explore the association of patient variables with anticoagulation control.
RESULTS: Roughly two-thirds of patients had poor anticoagulation control, as evidenced by TTR of <60%; the mean TTR was 48.6%. Poor control was significantly associated with female sex, advancing age, and comorbid conditions. Heart failure and having a non-board-certified physician were found to be independent predictors of poor control (odds ratio [OR] = 1.63; 95% confidence interval [CI] = 1.20-2.22; and OR = 1.41; 95% CI, 1.05-1.88, respectively).
CONCLUSIONS: Quality of anticoagulation in patients with AF receiving routine medical care was suboptimal, with nearly half the time spent outside the therapeutic range. Ways to improve anticoagulation control among patients with AF should be sought.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21504259

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  23 in total

1.  Use of vitamin K antagonist therapy in geriatrics: a French national survey from the French Society of Geriatrics and Gerontology (SFGG).

Authors:  Matthieu Plichart; Gilles Berrut; Nathalie Maubourguet; Claude Jeandel; Jean-Paul Emeriau; Joël Ankri; Hélène Bouvier; Geneviève Ruault; Olivier Hanon
Journal:  Drugs Aging       Date:  2013-12       Impact factor: 3.923

2.  Evaluation of Time in Therapeutic Range (TTR) in Patients with Non-Valvular Atrial Fibrillation Receiving Treatment with Warfarin in Tehran, Iran: A Cross-Sectional Study.

Authors:  Bahram-Fariborz Farsad; Mohammad Abbasinazari; Atousa Dabagh; Hooman Bakshandeh
Journal:  J Clin Diagn Res       Date:  2016-09-01

3.  Personalized Anticoagulation: Optimizing Warfarin Management Using Genetics and Simulated Clinical Trials.

Authors:  Kourosh Ravvaz; John A Weissert; Christian T Ruff; Chih-Lin Chi; Peter J Tonellato
Journal:  Circ Cardiovasc Genet       Date:  2017-12

4.  Potential Causes and Implications of Low Target Therapeutic Ratio in Warfarin-Treated Patients for Thrombosis Prophylaxis: A Single-Center Experience.

Authors:  Halil Atas; Ahmet Anıl Sahin; Dilek Barutçu Atas; Murat Sunbul; Alper Kepez; Mehmet Agirbasli
Journal:  Clin Appl Thromb Hemost       Date:  2017-03-01       Impact factor: 2.389

Review 5.  Novel oral anticoagulants: clinical pharmacology, indications and practical considerations.

Authors:  Sebastian Harder; Jochen Graff
Journal:  Eur J Clin Pharmacol       Date:  2013-04-26       Impact factor: 2.953

6.  Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation.

Authors:  Winnie W Nelson; Li Wang; Onur Baser; Chandrasekharrao V Damaraju; Jeffrey R Schein
Journal:  Int J Clin Pharm       Date:  2014-11-27

Review 7.  Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review.

Authors:  Elizabeth S Mearns; Jessica Hawthorne; Ju-Sung Song; Craig I Coleman
Journal:  BMJ Open       Date:  2014-06-20       Impact factor: 2.692

8.  Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression.

Authors:  Elizabeth S Mearns; C Michael White; Christine G Kohn; Jessica Hawthorne; Ju-Sung Song; Joy Meng; Jeff R Schein; Monika K Raut; Craig I Coleman
Journal:  Thromb J       Date:  2014-06-24

9.  Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry.

Authors:  Jan Beyer-Westendorf; Kati Förster; Franziska Ebertz; Vera Gelbricht; Thomas Schreier; Maria Göbelt; Franziska Michalski; Heike Endig; Kurtulus Sahin; Luise Tittl; Norbert Weiss
Journal:  Europace       Date:  2015-02-17       Impact factor: 5.214

Review 10.  Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation.

Authors:  K Huber; S J Connolly; A Kher; F Christory; G-A Dan; R Hatala; R G Kiss; B Meier; B Merkely; B Pieske; T Potpara; J Stępińska; N Vene Klun; D Vinereanu; P Widimský
Journal:  Int J Clin Pract       Date:  2013-04-05       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.